Ado-Trastuzumab emtansine (KADCYLA®)

Ado-Trastuzumab emtansine (KADCYLA®) is a HER2-targeted antibody-drug conjugate (ADC) which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 (a maytansine derivative) via the stable thioether linker MCC (4-[N-maleimidomethyl] cyclohexane1-carboxylate). Emtansine refers to the MCC-DM1 complex. The antibody trastuzumab, is a well characterized recombinant monoclonal antibody product produced by mammalian (Chinese hamster ovary) cells, and the small molecule components (DM1 and MCC) are produced by chemical synthesis. Ado-trastuzumab emtansine contains an average of 3.5 DM1 molecules per antibody. This product is used for research only. It can be used as a reference compound.

Product Details
Species Reactivity	Human
Host/Isotype	Cell culture/ IgG1
Class	Monoclonal
Type	Antibody-drug conjugate
Immunogen	Human Her2
DAR (Drug to Antibody Ratio)	~3.5
Clone	Trastuzumab biosimilar
Conjugate	Trastuzumab conjugated with SMCC-DM1
Purity	>98%
Molecular Weight	~148kDa
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	50 mM Sodium Phosphate, 0.05% Tween-20, pH7.4